Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2014 Mar 1.
Published in final edited form as: Gastrointest Endosc. 2013 Jan 5;77(3):410–418. doi: 10.1016/j.gie.2012.10.025

The role of colonoscopy in evaluating hematochezia: a population-based study in a large consortium of endoscopy practices

Ian M Gralnek 1,1,2, Osnat Ron-Tal Fisher 1,1, Jennifer L Holub 1,3, Glenn M Eisen 1,3,4
PMCID: PMC3927654  NIHMSID: NIHMS534988  PMID: 23294756

Abstract

Background

Data on the role of colonoscopy in hematochezia are almost exclusively derived from clinical experience in tertiary care practice.

Objective

To characterize the patient population who received colonoscopy for hematochezia in a consortium of diverse gastroenterology practices.

Design

Retrospective analysis.

Setting

Clinical Outcomes Research Initiative Database, 2002 to 2008.

Patients

Adults undergoing colonoscopy for the indication of hematochezia.

Main Outcome Measurements

Demographics, comorbidity, practice setting, adverse events, and colonoscopy procedure characteristics and findings. Age-stratified analyses and analyses of inpatient- versus outpatient-performed colonoscopies were also performed.

Results

A total of 966,536 colonoscopies were performed during the study period, 76,186 (7.9%) were performed for evaluation of hematochezia. The majority of patients were white non-Hispanic men younger than 60 years old who underwent colonoscopy at a community practice site (79.1%) and had a low-risk American Society of Anesthesiologists (ASA) score (81.5%), in whom colonoscopy reached the cecum (94.8%), and serious adverse events were rare. Colonoscopy findings were hemorrhoids (64.4%), diverticulosis (38.6%), and polyp or multiple polyps (38.8%). From the overall cohort, 38.3% were 60 years of age and older. The older age cohort had significantly more white non-Hispanic females, high-risk ASA scores, incomplete colonoscopies, and unplanned events. Colonoscopy findings demonstrated significantly higher rates of diverticulosis, polyp or multiple polyps, mucosal abnormality/colitis, tumor, and solitary ulcer (P .0001). There were 3941 (5.2%) who underwent inpatient performed colonoscopy. One third of this cohort (32.6%) was defined as having a high ASA score.

Limitations

Retrospective database review.

Conclusions

These results describe patient populations and characterize colonoscopy findings in individuals presenting with hematochezia primarily in a community practice setting.


Acute overt lower GI bleeding (LGIB), manifested as hematochezia, accounts for approximately 20% of all cases of GI bleeding, most often leads to hospital admission with inpatient diagnostic evaluations (eg, endoscopic, radiographic, nuclear medicine), and thus consumes significant medical resources.15 Approximately 75% of patients with acute LGIB will stop bleeding spontaneously and have an uneventful medical course.1,2 However, morbidity and mortality are increased in older patients and those with comorbid medical conditions.1,2,6,7 Causes of acute hematochezia include colonic diverticulosis, vascular ectasias, ischemic colitis, colorectal neoplasms, inflammatory bowel disease, anorectal conditions (eg, hemorrhoids), and post polypectomy bleeding.2,4,5

Colonoscopy is the preferred management strategy for most patients with acute hematochezia.1,7 The advantage of colonoscopy over other tests is its ability to provide a diagnosis and endotherapy when indicated.1,7 Yet, in contrast to acute upper GI bleeding and outside of tertiary care medical centers, there are only limited population-based data on LGIB etiologies, endoscopic findings, and endoscopic treatments.1,6 Moreover, there are no published data describing or comparing LGIB by age-stratified patient populations. The aims of this study were to describe the patient population presenting with acute, overt LGIB in a large consortium of diverse gastroenterology practices in the United States. In addition, we performed age-stratified analyses comparing a cohort of older patients (60 years of age and older) presenting with acute LGIB with a younger LGIB population (18–59 years) and also evaluated the subgroup of patients who underwent colonoscopy in an inpatient setting and not in the ambulatory setting, as well as comparing tertiary practice and community practice settings.

METHODS

Clinical Outcomes Research Initiative: national endoscopic database

We used the Clinical Outcomes Research Initiative (CORI) for this population-based study. CORI was established in 1995 to study the use and outcomes of endoscopy in diverse gastroenterology practice settings in the United States. All participating CORI endoscopy sites use a standardized computerized report generator to create all endoscopic reports and comply with CORI quality-control requirements. The sites’ data files are transmitted electronically on a weekly basis to a central data repository, the National Endoscopic Database (NED), located in Portland, Oregon. The data transmitted from the local endoscopy site to the NED do not contain patient or provider identifiers and qualify as a Limited Data Set under 45 C.F.R. Section 164.514(e)(2). After completion of quality-control checks, data from all sites are merged in the data repository for analysis. The data repository is checked for anomalies on a daily basis, and endoscopy procedure counts are monitored on a weekly basis for atypical activity. Any unusual activity prompts follow-up contact by CORI staff. Multiple studies on a variety of endoscopy-related topics that have used CORI data have resulted in peer-reviewed publications.815

Patient inclusion and exclusion criteria

We identified all adult patients (18 years of age and older) in the CORI database over a 7-year period between January 1, 2002, and December 31, 2008, who underwent colonoscopy for the sole indication of hematochezia. The endoscopist performing the colonoscopy is required to choose a primary indication for the CORI colonoscopy report.

Definitions

We characterized acute overt LGIB by patient demographics, disease comorbidity per the American Society of Anesthesiologists (ASA) score, gastroenterology practice setting, endoscopic diagnosis, reported extent of colonoscopy examination, repeat colonoscopy procedures performed within 72 hours of the index colonoscopy, and procedural adverse events. We defined gastroenterology practice setting as follows: tertiary care included academic and Veterans Affairs/military practice sites versus community practice, which included community/health maintenance organization practices. In the CORI data, patients may have more than 1 endoscopic finding reported at colonoscopy, and thus we included all findings in our analyses. In addition, we performed age-stratified analyses whereby we compared older subjects (60 years of age and older) presenting with hematochezia with a younger LGIB population (18–59 years), and we also evaluated the sub- group of patients who underwent colonoscopy as an inpatient and not in the outpatient setting. Our analysis of the subgroup of patients undergoing colonoscopy in the inpatient setting was an attempt to further characterize patients with potentially more severe hematochezia.

Data analyses

Comparisons of categorical data were performed by using Pearson’s χ2 test of independence. An a priori determined P <.05 was considered statistically significant. All analyses were performed by using SAS software version 9.2 (SAS Institute, Cary, NC).

RESULTS

A total of 966,536 colonoscopy procedures in 846,159 patients were performed for all indications at 1 of 72 CORI sites during the study period. Of those colonoscopies performed, 76,186 (7.9% of procedures and 9.0% of patients) underwent colonoscopy for the sole indication of hematochezia. In this hematochezia cohort, 43,521 (57.1%) were male and 33,665 (42.9%) were female. There were 62,314 (81.8%) white non-Hispanic and 47,039 (61.7%) were younger than 60 years of age. The vast majority of patients 60,290 (79.1%) underwent colonoscopy at a community practice site, and 62,080 (81.5%) were defined as having a low-risk ASA score (ASA score of 1 or 2). In total, 94.8% of colonoscopy examinations were reported to have reached the cecum. We also found that 478 (0.6%) of the cohort underwent repeat colonoscopy within 72 hours of their index colonoscopy. In this subgroup, 404 (84.5%) had hematochezia as an indication and 394 (82.4%) as the primary indication for repeat colonoscopy. Serious adverse events (eg, bleeding, perforation, death) were rare (76; 0.1%) (Table 1).

TABLE 1.

Hematochezia cohort demographics and procedural characteristics

Total no. 76,186
Age group, y, no. (%)
<50 23,495 (30.8)
50–59 23,544 (30.9)
60–69 14,876 (19.5)
70–79 9739 (12.8)
>=80 4532 (6)
Sex, no. (%)
Female 33,665 (42.9)
Male 43,521 (57.1)
Race/ethnicity, no. (%)
White non-Hispanic 62,314 (81.8)
Black non-Hispanic 5034 (6.6)
Asian/Pacific Islander non-Hispanic 1427 (1.9)
Native American non-Hispanic 731 (1.0)
Multiracial non-Hispanic 139 (0.2)
Hispanic 6347 (8.3)
Missing/unknown 194 (0.3)
ASA score, no. (%)
I 20,958 (27.5)
II 41,122 (54.0)
III 5289 (6.9)
IV 289 (0.4)
V 1 (0)
Unknown 8527 (11.2)
Practice setting, no. (%)
Community/HMO 60,290 (79.1)
Academic 6709 (8.8)
VA/military 9187 (12.1)
Depth of insertion, no. (%)
Reached cecum 72,427 (94.8)
Repeat colonoscopy within 72 h of index examination, no. (%) 478 (0.6)
Unplanned events, no. (%)
Any unplanned event 808 (1.1)
Cardiopulmonary unplanned event 696 (0.9)
Serious adverse event (bleeding, perforation, death) 76 (0.10)

ASA, American Society of Anesthesiologists; HMO, health maintenance organization; VA, Veterans Affairs.

Colonoscopy findings included hemorrhoids (49,057 [64.4%]), diverticulosis (29,437 [38.6%]), polyp or multiple polyps (29,560 [38.8%]), mucosal abnormality/colitis (5985 [7.9%]), tumor (1522 [2.0%]), vascular ectasias (899 [1.2%]), and solitary ulcer (325 [0.4%]). There were 92 (0.1%) who were reported to be having active bleeding at the time of colonoscopy (Table 2). Patients may have had more than 1 endoscopic finding reported at colonoscopy.

TABLE 2.

Colonoscopy findings*

Hemorrhoids 49,057 (64.4)
Diverticulosis 29,437 (38.6)
Polyp 25,205 (33.1)
Other finding 8150 (10.7)
Mucosal abnormality/colitis 5985 (7.9)
Multiple polyps 4355 (5.7)
Tumor 1522 (2.0)
Angiodysplasia 899 (1.2)
Solitary ulcer 325 (0.4)
Active bleeding 92 (0.1)
*

Patients may have had multiple findings reported at colonoscopy.

Age-stratified analyses

Of the 76,186 persons who underwent colonoscopy for hematochezia, 29,147 (38.3%) were 60 years of age and older (range 60–102 years). Compared with the younger hematochezia patients, the older age cohort had significantly more females (44.8% vs 41.7%) and white non-Hispanics (85.4% vs 79.6%) (P <.0001), with most undergoing colonoscopy at a community practice site (n 22,686 [77.8%]). Significantly more of the older age cohort (13.2% vs 3.7%, P <.0001) were defined as having a high-risk ASA score (ASA score of III or IV). Moreover, significantly fewer colonoscopy examinations reached the cecum in the older age cohort (92.2% vs 96.2%, P <.0001), and unplanned events, including any unplanned event or cardiopulmonary or serious adverse event, were significantly higher in the older patients (3.2% vs 1.4%, P <.0001) (Table 3). Compared with the younger age cohort, colonoscopy findings in the older age patients demonstrated significantly higher rates of diverticulosis (59.6% vs 25.7%), polyp or multiple polyps (44.0% vs 35.6%), mucosal abnormality/colitis (8.9% vs 7.2%), tumor (3.3% vs 1.2%), angiodysplasia (2.0% vs 0.7%), and solitary ulcer (0.6% vs 0.3%) (all comparisons P <.0001). There were significantly fewer hemorrhoids reported as an endoscopic finding in the older age cohort (17,784 [61.0%] vs 31,273 [66.5%], P <.0001) (Table 4).

TABLE 3.

Age-stratified demographics and procedural characteristics

Age-stratified cohort, no. (%) <60 y >=60 y P value
No. 47,039 29,147
Sex, no. (%)
Female 19,608 (41.7) 13,057 (44.8) <.0001
Male 27,431 (58.3) 16,090 (55.2)
Race/ethnicity, no. (%)
White non-Hispanic 37,432 (79.6) 24,882 (85.4) <.0001
Black non-Hispanic 3447 (7.3) 1687 (5.4)
Asian/Pacific Islander non-Hispanic 1008 (2.1) 419(1.4)
Native American non-Hispanic 496 (1.1) 235(0.8)
Multiracial non-Hispanic 101 (0.2) 38 (0.1)
Hispanic 4460 (9.5) 1887 (6.5)
Missing/unknown 95 (0.2) 99 (0.3)
ASA classification, no. (%)
I 17,038 (36.2) 3920(13.5) <.0001
II 22,962 (48.8) 18,160 (62.3)
III 1647 (3.5) 3642(12.5)
IV 88 (0.2) 201(0.7)
V 0 1 (0.0)
Unknown 5304 (11.3) 3223(11.1)
Site type
Community/HMO 37,039 (79.9) 22,686 (77.8) <.0001
Academic 4093 (8.7) 2616 (9.0)
VA/military 5342 (11.4) 3845(13.2)
Depth of insertion
Reached the cecum 45,237 (96.2) 27,010 (92.7) <.0001
Unplanned events
Any unplanned event 345 (0.7) 463(1.6) <.0001
Cardiopulmonary 297 (0.6) 399(1.4) <.0001
Serious adverse event (bleeding, perforation, death) 23 (0.1) 53 (0.2) <.0001

ASA, American Society of Anesthesiologists; HMO, Health maintenance organization; VA, Veterans Affairs.

TABLE 4.

Colonoscopy findings by age strata*

N = 76,186
<60 y (n =47,039) >=60 y (n= 29,147) P value
Hemorrhoids 31,273 (66.5) 17,784 (61.0) <.0001
Diverticulosis 12,068 (25.7) 17,369 (59.6) <.0001
Polyp 14,373 (30.6) 10,832 (37.2) <.0001
Other findings 4524 (9.6) 3626(12.4) <.0001
Mucosal abnormality/colitis 3390 (7.2) 2595 (8.9) <.0001
Multiple polyp 2372 (5.0) 1983 (6.8) <.0001
Tumor 558 (1.2) 964(3.3) <.0001
Angiodysplasia 322 (0.7) 577(2.0) <.0001
Actively bleeding 21 (0.0) 71 (0.2) <.0001
Solitary ulcer 151 (0.3) 174(0.6) <.0001
*

Patients may have had multiple endoscopic findings reported at colonoscopy.

Inpatient- versus outpatient-performed colonoscopy

Of the 76,186 colonoscopies performed for the indication of hematochezia, 3941 (5.2%) were performed in an inpatient setting and 57,909 (76.0%) in an outpatient setting. There were 14,336 that were not categorized (inpatient or outpatient) and are thus considered as missing data. Compared with those patients undergoing colonoscopy in the outpatient setting, the inpatient cohort had significantly fewer females (41.4% vs 42.4%;P <.0001) and white non-Hispanics (69.9% vs 82.9%, P <.0001). One third of the inpatient-performed colonoscopy cohort (32.6% vs 5.5%, P <.0001) were defined as having a significantly higher ASA score (ASA score of 3 or 4). Moreover, significantly fewer colonoscopy examinations reached the cecum in the inpatient cohort (85.8% vs 95.6%, P <.0001), and there were significantly more unplanned events during inpatient colonoscopies (1.6% vs 1.1%, P=.002) (Table 5). In addition, compared with the outpatient-performed colonoscopy cohort, inpatient-performed colonoscopy findings demonstrated significantly higher rates of diverticulosis (56.2% vs 37.6%), mucosal abnormality/colitis (19.4% vs 7.0%), tumor (4.9% vs 1.8%), angiodysplasia (3.2% vs 1.1%), active bleeding (0.6% vs 0.1%), and solitary ulcer (1.9% vs 0.3%) (all comparisons P <.0001). There were significantly fewer polyps or multiple polyps (32.3% vs 40.0%) and hemorrhoids (50.9% vs 66.7%) reported in the inpatient-performed colonoscopy cohort (both comparisons P <.0001) (Table 6).

TABLE 5.

Inpatient versus outpatient colonoscopy demographics

Characteristic Inpatient, no. (%) Outpatient, no. (%) Unknown/missing, no. (%) P value
Sex 3941 (5.2) 57,909 (76.0) 14,336 (18.8)
Female 1630 (41.4) 24,541 (42.4) 6494(45.3) <.0001
Male 2311 (58.6) 33,368 (57.6) 7842(54.7)
Race/ethnicity
White non-Hispanic 2756 (69.9) 47,977 (82.9) 11,581 (80.8) <.0001
Black non-Hispanic 624 (15.8) 3352 (5.8) 1058 (7.4)
Asian/Pacific Islander non-Hispanic 76 (1.9) 1151 (2.0) 200(1.4)
Native American non-Hispanic 63 (1.6) 591 (1.0) 77 (0.5)
Multiracial non-Hispanic 2 (0.1) 110 (0.2) 27 (0.2)
Hispanic 412 (10.5) 4556 (7.9) 1,379 (9.6)
Missing/unknown 8 (0.2) 172 (0.3) 14 (0.1)
ASA classification
I 479 (12.2) 15,444 (26.7) 5035(35.1) <.0001
II 1792 (45.5) 33,055 (57.1) 6275(43.8)
III 1178 (29.9) 3102 (5.4) 1009 (7.0)
IV 108 (2.7) 71 (0.1) 110(0.8)
V 0 (0) 0 (0) 1 (0.0)
Site type
Community/HMO 2645 (67.1) 44,976 (77.7) 12,669 (88.4) <.0001
Academic 658 (16.7) 5086 (8.8) 965(6.7)
VA/Military 638 (16.2) 7847 (13.6) 702(4.9)
Depth of insertion
Reached the cecum 3,381 (85.8) 55,378 (95.6) 13,488 (94.1) <.0001
Unplanned events
Any unplanned event 63 (1.6) 606 (1.1) 139(1.0) .002
Cardiopulmonary unplanned event 56 (1.4) 523 (0.9) 117(0.8) .002
Serious adverse event (bleeding, perforation, death) 6 (0.2) 57 (0.1) 13 (0.1) .544

ASA, American Society of Anesthesiologists; HMO, health maintenance organization; VA, Veterans Affairs.

TABLE 6.

Colonoscopy findings stratified by inpatient versus outpatient status (N = 76,186)

Characteristic Inpatient Outpatient Unknown/missing P value
Findings* 3941 (5.2) 57,909(76.0) 14,336 (18.8)
Hemorrhoids 2005(50.9) 38,643(66.7) 8409(58.7) <.0001
Diverticulosis 2215(56.2) 21,753(37.6) 5469(38.2) <.0001
Polyp 1104(28.0) 19,641(33.9) 4460(31.1) <.0001
Other finding 917(23.3) 5408 (9.3) 1825(12.7) <.0001
Mucosal abnormality/colitis 766(19.4) 4035 (7.0) 1184 (8.3) <.0001
Multiple polyp 168(4.3) 3528 (6.1) 659(4.6) <.0001
Tumor 193(4.9) 1,055(1.8) 274(1.9) <.0001
Angiodysplasia 126(3.2) 629 (1.1) 144(1.0) <.0001
Active bleeding 23(0.6) 49 (0.1) 20 (0.1) <.0001
Solitary ulcer 76(1.9) 151 (0.3) 98 (0.7) <.0001
*

Patients may have had multiple findings per procedure.

Tertiary care versus community practice setting

In total, 60,290 (79.1%) patients underwent colonoscopy for hematochezia in a community practice setting. Compared with those patients undergoing colonoscopy in a tertiary care setting, the community practice patients were significantly younger, more likely to be white non-Hispanic females, and be healthier based on the ASA score (P <.0001). Moreover, in the community practice patient cohort, there was a significantly higher rate of reaching the cecum and significantly fewer unplanned events, both cardiopulmonary and severe events (P< .0001) (Table 7).

TABLE 7.

Tertiary care versus community practice colonoscopy demographics

Characteristic Tertiary care Community practice P value
No. (%) 15,896 (20.1) 60,290 (79.1)
Age group, no. (%)
<50 4344(27.3) 19,151 (31.8) <.0001
50–59 5091(32.0) 18,453 (30.6)
60–69 3331(21.0) 11,545 (19.2)
70–79 2161(13.6) 7578 (12.6)
>=80 969(6.1) 3563 (5.9)
Sex
Female 3985(25.1) 28,680 (47.6) <.0001
Male 11,911 (74.9) 31,610 (52.4)
Race/ethnicity, no. (%)
White non-Hispanic 12,379 (77.9) 49,935 (82.8) <.0001
Black non-Hispanic 1568 (9.9) 3466 (5.8) <.0001
Asian/Pacific Islander non-Hispanic 323(2.0) 1104 (1.8)
Native American non-Hispanic 80 (0.5) 651 (1.1)
Multiracial non-Hispanic 38 (27.3) 101 (0.2)
Hispanic 1502 (9.5) 4845 (8.0)
ASA classification
I 3091(19.5) 17,867 (29.6) <.0001
II 9905(62.3) 31,217 (51.8)
III 1879(11.8) 3410 (5.7)
IV 146(0.9) 143 (0.2)
V 1 (0.0) 0 (0.0)
Depth of insertion
Reached the cecum 14,524 (91.4) 57,723 (95.7) <.0001
Unplanned events
Any unplanned event 260(1.6) 548 (0.9) <.0001
Cardiopulmonary unplanned event 211(1.3) 485 (0.8) <.0001
Serious adverse event (bleeding, perforation, death) 37 (0.2) 39 (0.1) <.0001

ASA, American Society of Anesthesiologists.

DISCUSSION

This population-based study, using the CORI NED, defines and describes patients presenting with acute overt LGIB (hematochezia) in a large consortium of diverse gastroenterology practices, primarily community-based practice, in the United States. We further characterized this hematochezia population by stratifying by age, practice setting, and, to better select for more severe cases of hematochezia, inpatient- versus outpatient-performed colonoscopy. Compared with published data from tertiary care centers, we found in the overall cohort a different prevalence for reported colonoscopic lesions as the cause of hematochezia.2,6 Specifically, we found internal hemorrhoids reported in 64.4% followed by diverticulosis in 38.8%. When we performed age-stratified analyses and restricted our analyses to patients 60 years of age and older, diverticulosis was the primary reported cause of hematochezia at 59.6%. Overall, 94.8% of colonoscopy examinations were reported to have reached the cecum, and this only decreased to 92.6% in the older age cohort. Less than 1% of patients underwent repeat colonoscopy within 72 hours of their index examination. Similar to other reported data, we found that serious adverse events with colonoscopy in the clinical setting of hematochezia were rare.1

We believe this to be the first population-based report examining the role of colonoscopy in patients with hematochezia that stratifies by age. We found that 29,147 (38.3%), a significant proportion, of the patients undergoing colonoscopy for hematochezia were 60 years of age and older. This older age cohort had significantly more females and white non-Hispanics compared with the younger hematochezia patients. We also found significantly more of the older age cohort having a high-risk ASA score. As in reports from tertiary care centers, we found that the primary colonoscopic diagnosis for hematochezia in the older patients was diverticular disease.5 Furthermore, we found that for patients undergoing inpatient colonoscopy, one third had significantly higher ASA scores, there was a significantly lower rate of cecal intubation, and there were significantly more adverse events reported. Not surprisingly, we also found that the patients undergoing colonoscopy in a community practice setting were significantly younger and healthier, with more complete colonoscopies and fewer unplanned events.

We believe that there are a number of strengths to this study and in using the CORI NED as the primary endoscopic data source. CORI uses standardized and strict quality-control measures for all of their data, endoscopic data are derived from a variety of GI practice type settings with highly varied patient demographics, the majority of CORI sites are community based, providing a real-world view of endoscopic practice, and CORI has been used as the primary endoscopic data source for multiple previously published studies. This includes CORI data that we evaluated in patients presenting with nonvariceal upper GI hemorrhage.13,14 However, this study has several limitations. The CORI endoscopic report is the sole source of data in this study. Therefore, clinical information (patient-level data) beyond the endoscopic report is limited, including clinical correlation with the severity of the hemtaochezia (eg, hypotension, anemia, transfusion requirements), medication use, timing of colonoscopy, adequacy of colon preparation, or other diagnostic studies (eg, radiographic, nuclear medicine, angiographic), which may have been performed before or after colonoscopy. In addition, because of limitations of the CORI database, we do not know that the reported endoscopic findings definitively confirm the underlying etiology of the hematochezia. The information in the CORI database represents the input of the physician who performs the endoscopy, and thus the use of check-box notation and free text is variable. Additionally, analysis of follow-up data in CORI is limited. Endoscopies that may have been performed for recurrent hematochezia at non-CORI participating sites are not captured in our data and analysis. As a result, our repeat endoscopy data may be “at least” figures because some patients may have sought care at a non-CORI participating site and thus would not have been captured. In our study, lower GI hemorrhage was diagnosed based on the endoscopist’s suspicion to proceed with colonoscopy based on the patient’s presenting symptoms, physical examination, and laboratory data. Our study used repeat colonoscopy within 72 hours of the index endoscopy as a surrogate marker for recurrent hematochezia. Repeat colonoscopy may have had nothing to do with recurrent hematochezia and may only indicate an incomplete examination at the index colonoscopy with the need for a second-look examination. Thus, given the retrospective nature of this study, we cannot discern the true indication for repeat colonoscopy. Finally, CORI sites are not necessarily a random sample of GI practices in the United States and are susceptible to site-selection bias. Despite these limitations, the CORI database remains unique in that it provides us with insight into how real-life endoscopy is being practiced in the United States. The large number of patients and colonoscopies permits observation of management trends in clinical situations outside traditional tertiary care centers, and, therefore, the CORI database is a powerful tool for generating future research studies.

In conclusion, the majority of persons presenting with hematochezia and undergoing colonoscopy in a GI community practice appear to be younger white non-Hispanic men, in good health who are found to have hemorrhoids, diverticulosis, polyps, and/or mucosal abnormalities/colitis that may explain their hemtochezia. Yet, compared with younger patients with hematochezia who undergo colonoscopy, older patients are more likely to be female, white non-Hispanic, with significantly more severe comorbid medical conditions and who are more likely to have diverticulosis, polyps, mucosal abnormalities/colitis, tumors, or angiodysplasia that may explain their hematochezia. Furthermore, there were significantly higher rates of incomplete colonoscopy and adverse events in older patients. These data provide new information on colonoscopy performed in patients with hematochezia evaluated primarily in community practice.

Abbreviations

ASA

American Society of Anesthesiologists

CORI

Clinical Outcomes Research Initiative

LGIB

lower GI bleeding

NED

National Endoscopic Database

Footnotes

DISCLOSURE: The authors disclosed no financial relationships relevant to this publication. This project (Holub, Eisen) was supported in part with funding from NIDDK UO1 DK57132. In addition, the practice network (Clinical Outcomes Research Initiative) has received support from the following entities to support the infrastructure of this practice-based network: AstraZeneca, Bard International, Pentax USA, ProVation, Endosoft, GIVEN Imaging, and Ethicon. These commercial entities had no involvement in the current research.

References

  • 1.Strate LL, Naumann CR. The role of colonoscopy and radiological procedures in the management of acute lower intestinal bleeding. Clin Gastroenterol Hepatol. 2010;8:333–43. doi: 10.1016/j.cgh.2009.12.017. [DOI] [PubMed] [Google Scholar]
  • 2.Arroja B, Cremers I, Ramos R, et al. Acute lower gastrointestinal bleeding management in Portugal: a multicentric prospective 1-year survey. Eur J Gastroenterol Hepatol. 2011;23:317–22. doi: 10.1097/MEG.0b013e328344ccb5. [DOI] [PubMed] [Google Scholar]
  • 3.Laine L, Shah A. Randomized trial of urgent vs. elective colonoscopy in patients hospitalized with lower GI bleeding. Am J Gastroenterol. 2010;105:2636–4. doi: 10.1038/ajg.2010.277. [DOI] [PubMed] [Google Scholar]
  • 4.Barnert J, Messmann H, Medscape Diagnosis and management of lower gastrointestinal bleeding. Nat Rev Gastroenterol Hepatol. 2009;6:637–46. doi: 10.1038/nrgastro.2009.167. [DOI] [PubMed] [Google Scholar]
  • 5.Chait MM. Lower gastrointestinal bleeding in the elderly. World J Gastrointest Endosc. 2010;2:147–54. doi: 10.4253/wjge.v2.i5.147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Strate LL, Ayanian JZ, Kotler G, et al. Risk factors for mortality in lower intestinal bleeding. Clin Gastroenterol Hepatol. 2008;6:1004–10. doi: 10.1016/j.cgh.2008.03.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Rockey DC. Lower gastrointestinal bleeding. Gastroenterology. 2006;130:165–71. doi: 10.1053/j.gastro.2005.11.042. [DOI] [PubMed] [Google Scholar]
  • 8.Lieberman DA, Holub J, Eisen G, et al. Utilization of colonoscopy in the United States: results from a national consortium. Gastrointest Endosc. 2005;62:875–83. doi: 10.1016/j.gie.2005.06.037. [DOI] [PubMed] [Google Scholar]
  • 9.Lieberman DA, Holub J, Eisen G, et al. Prevalence of polyps greater than 9 mm in a consortium of diverse clinical practice settings in the United States. Clin Gastroenterol Hepatol. 2005;3:798–805. doi: 10.1016/s1542-3565(05)00405-2. [DOI] [PubMed] [Google Scholar]
  • 10.Harewood GC, Lieberman DA. Colonoscopy practice patterns since introduction of Medicare coverage for average-risk screening. Clin Gastroenterol Hepatol. 2004;2:72–7. doi: 10.1016/s1542-3565(03)00294-5. [DOI] [PubMed] [Google Scholar]
  • 11.Cram P, Fendrick AM, Inadomi J, et al. The impact of a celebrity promotional campaign on the use of colon cancer screening: the Katie Couric effect. Arch Intern Med. 2003;163:1601–5. doi: 10.1001/archinte.163.13.1601. [DOI] [PubMed] [Google Scholar]
  • 12.Lieberman D, Fennerty MB, Morris CD, et al. Endoscopic evaluation of patients with dyspepsia: results from the national endoscopic data repository. Gastroenterology. 2004;127:1067–75. doi: 10.1053/j.gastro.2004.07.060. [DOI] [PubMed] [Google Scholar]
  • 13.Enestvedt BK, Gralnek IM, Mattek N, et al. An evaluation of endoscopic indications and findings related to non-variceal upper gastrointestinal hemorrhage in a large multi-center consortium. Gastrointest Endosc. 2008;67:422–9. doi: 10.1016/j.gie.2007.09.024. [DOI] [PubMed] [Google Scholar]
  • 14.Enestvedt BK, Gralnek IM, Mattek N, et al. Endoscopic therapy for peptic ulcer hemorrhage: practice variations in a multi-center U.S. consortium. Dig Dis Sci. 2010;55:2568–76. doi: 10.1007/s10620-010-1311-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Lieberman DA, Holub JL, Moravec MD, et al. Prevalence of colon polyps detected by colonoscopy screening in asymptomatic black and white patients. JAMA. 2008;300:1417–22. doi: 10.1001/jama.300.12.1417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Gupta M, Holub JL, Eisen G. Do indication and demographics for colonoscopy affect completion? A large national database evaluation. Eur J Gastroenterol Hepatol. 2010;22:620–7. doi: 10.1097/MEG.0b013e3283352cd6. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES